Prevalence of the expression of the CSC phenotype CD44+/CD24−/low and CD44+/CD24−/low/ALDH1+ in the breast cancer histological special types.
| CD44+/CD24−/low | CD44+/CD24−/lowALDH1+ | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | Positive (%) | Negative (%) | Risk diff (CI 95%) | p Value* | n | Positive (%) | Negative (%) | Risk diff (CI 95%) | p Value* | |
| IDC-NST† | 461 | 209 (45.3) | 252 (54.7) | 459 | 22 (4.8) | 437 (95.2) | ||||
| Special histological type | 87 | 57 (65.5) | 30 (34.5) | −0.20 (−0.30 to −0.09) | <0.001 | 52 | 6 (11.5) | 46 (88.5) | −0.07 (−0.18 to −0.00) | 0.043 |
| Mucinous | 21 | 13 (61.9) | 8 (38.1) | −0.16 (−0.34 to 0.05) | 0.136 | 17 | 0 (0.0) | 17 (100.0) | 0.05 (−0.14,0.07) | 1.000‡ |
| Medullary | 15 | 12 (80.0) | 3 (20.0) | −0.35 (−0.48 to −0.09) | 0.008 | 11 | 4 (36.4) | 7 (63.6) | −0.32 (−0.60 to −0.10) | 0.002‡ |
| Tubular | 14 | 14 (100.0) | 0 (0.0) | −0.55 (−0.59 to −0.33) | <0.001‡ | 10 | 0 (0.0) | 10 (100.0) | 0.05 (−0.23 to 0.07) | 1.000‡ |
| Apocrine | 13 | 5 (38.5) | 8 (61.5) | 0.07 (−0.20 to 0.28) | 0.623 | − | − | − | − | − |
| Lobular | 7 | 2 (33.3) | 4 (66.7) | 0.12 (−0.25 to 0.36) | 0.690‡ | 5 | 0 (0.0) | 5 (100.0) | 0.05 (−0.39 to 0.07) | 1.000‡ |
| Metaplastic | 7 | 5 (71.4) | 2 (28.6) | −0.26 (−0.47 to 0.10) | 0.255‡ | 7 | 2 (28.6) | 5 (71.4) | −0.24 (−0.59 to −0.03) | 0.046‡ |
| Micropapillary | 6 | 2 (33.3) | 4 (66.7) | 0.12 (−0.25 to 0.36) | 0.694‡ | 1 | 0 (0.0) | 1 (100.0) | 0.05 (−0.75 to 0.07) | 1.000‡ |
| Papillary | 4 | 4 (100.0) | 0 (0.0) | −0.55 (−0.59 to −0.06) | 0.043‡ | 1 | 0 (0.0) | 1 (100.0) | 0.05 (−0.75 to 0.07) | 1.000‡ |
*For comparison with IDC-NST.
†As previously published by Ricardo S et al.13
‡Two-sided Fisher's exact test.